Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Drug Test Anal. 2018 Sep 11;11(1):119–128. doi: 10.1002/dta.2475

Figure 2.

Figure 2.

Orbitrap LCMS traces of underivatized OT in serum from non-pregnant/non-lactating/non-medicated women without spiking (A) and after spiking with 50 pg/mL OT (B) and applying a 3–5 ppm mass window when monitoring in targeted SIM mode. Differences in retention times are probably due to slight differences in mobile phase composition during gradient elution.